Skip to main content

Clopidogrel and the Newer P2Y12 Antiplatelet Agents: Pharmacology, Clinical Uses, and Adverse Effects

by , ,

Write The First Customer Review
Clopidogrel and the Newer P2Y12 Antiplatelet Agents: Pharmacology, Clinical Uses, and Adverse Effects - Savage, Michael P., M.D. (Editor), and Fischman, David L., M.D. (Editor), and Mamas, Mamas (Editor)
Filter Results
Shipping
Item Condition
Seller Rating
Other Options
Change Currency

Cardiovascular disease remains the leading cause of death in the developed world. By preventing thromboembolic events such as heart attacks and strokes, antiplatelet drugs have become a cornerstone in the treatment of cardiovascular disease. Clopidogrel is a member of the thienopyridine family which inhibit ADP-induced platelet activation by irreversibly binding to the P2Y12 receptor. Clopidogrel is one of the most commonly used medications with over 9 million prescriptions written annually. It is utilized in the treatment ...

loading
Clopidogrel and the Newer P2Y12 Antiplatelet Agents: Pharmacology, Clinical Uses, and Adverse Effects 2019, Nova Science Publishers Inc, New York

ISBN-13: 9781536149722

Hardcover